AnaptysBio Inc Sustainability Reports
AnaptysBio, Inc. focuses on managing its financial collaborations and royalty streams for therapeutic assets like Jemperli with GSK and imsidolimab with Vanda. The company previously developed antibody-based therapeutics for autoimmune and inflammatory diseases before spinning off its biopharma operations.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 529900HH4WQT03IG1A12
FIGI: BBG0026ZDHT8
5 reports from 2017 to 2024
